Business Wire

PPG Experts to Showcase Future of Automotive Color Styling, Application Technology at Surcar Europe 2021

1.7.2021 16:02:00 EEST | Business Wire | Press release

Share

PPG (NYSE: PPG) today announced that its experts will share the future of sustainable automotive color styling and application technology in presentations at the Surcar Europe 2021 automotive engineering and design show, which is being held this week in Cannes, France.

Sabine Griesbeck, PPG digital transformation technical manager, will discuss the future of color development using digital color styling. A presentation by Sven Reil, PPG automotive application manager, Europe, Middle East and Africa, will cover paint as an enabler for precision application. Both presentations will be given on July 1.

PPG’s digital styling program will enable automotive designers to execute exceptionally realistic three-dimensional modeling of automotive colors and effects on virtual car designs and surfaces, significantly speeding up the process of developing new colors and reducing waste.

“Prior to the development of PPG's digital color styling program, the time taken from the designer’s vision to a final color could be as long as nine months,” said Griesbeck. “The color team developed several different variations of a color. These are then applied to test panels that are sent to the customer for review. This generated waste, and having small panels does not give a good real-world representation of the color.”

PPG’s digital styling library features a proprietary “speed shape” that accurately depicts the interaction of color, geometry and light. It also offers the option to download digital color files that are fully compatible with industry-standard color-rendering software. This enables design teams to collaborate with PPG experts directly, remotely and in real time.

“This is the first step in fully digitizing the entire color styling process for PPG customers,” Griesbeck said. “Imagine if in the future you can adjust a color virtually according to your wishes, and the new color design is digitally born and ready to use in production. There are also significant sustainability benefits, as we expect this new way of working will reduce the carbon dioxide (CO2) footprint through lower material and energy consumption.”

Individualization and customization are also leading to an increased demand for two-tone schemes. PPG’s breakthrough precision application technology for automotive coatings significantly streamlines the painting of these schemes, producing crisp paint edges without the use of masking and other time-intensive steps currently required to achieve a two-tone finish.

“The conventional process requires that a vehicle be fully painted before paint shop personnel mask off areas that will not receive the second color,” said Reil. “The vehicle must then be run through the paint line or a repair line a second time to apply the contrasting color. In addition to reducing paint shop capacity, this second run can add significant material, labor and energy costs to the total unit cost of the vehicle.”

The precision process uses a specially designed PPG coating as well as innovative application heads that apply the paint directly without overspray. This can reduce paint shop time by approximately 50 minutes per two-tone vehicle. This process also advances customer sustainability goals by reducing CO2 emissions and eliminating energy-intensive air-filtering systems that handle overspray from the paint application process, reducing costs and improving efficiency.

“The process uses a direct printing approach rather than conventional spraying, eliminating overspray and masking,” Reil said. “It allows the application of coatings in an extremely precise manner, giving the ability to combine both sustainability and customization. In the future, complete cars might be painted using precision application technology, offering manufacturers even more options to enhance the appeal of their vehicle models.”

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $13.8 billion in 2020. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.

CATEGORY Automotive OEM Coatings

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PPG Media Contacts:
Andrew Wood
Corporate Communications, EMEA
+31 6 5121 6579
awood@ppg.com

Keith Rigby
Automotive OEM Coatings
+1 412-434-1718
krigby@ppg.com
www.ppg.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye